Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

March 31, 2024

Conditions
Bullous Pemphigoid
Interventions
DRUG

Avdoralimab (IPH5401)

Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.

OTHER

Control

"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"

Trial Locations (4)

13000

APHM, Hôpital Nord, Marseille

13005

APHM, Timone, Marseille

34005

CHU Montpellier, Dermatologie, Montpellier

06200

CHU de Nice- Dermatologie, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT04563923 - Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Biotech Hunter | Biotech Hunter